PHIP and obesity due to melanocortin 4 receptor deficiency: These findings may also inform the mechanism-based treatment of PHIP variant carriers with a melanocortin receptor agonist currently in clinical trials, which leads to significant weight loss in severe obesity due to complete POMC deficiency (Kühnen et al., 2016).